Latest:
Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CML
Kendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Kenneth B. DeSantes, MD
Latest:
University of Wisconsin Team Develops Novel Strategy for High-Risk Neuroblastoma
Investigators at the University of Wisconsin American Family Children’s Hospital are developing a new approach to treating patients with neuroblastoma that has the potential to improve outcomes for patients whose disease has not responded to conventional therapy.
Kenneth M. Kernen, MD
Latest:
Focal Therapy Evolves Into More Precise Treatment in Prostate Cancer
Historically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.
Kenneth R. Carson, MD
Latest:
Dr. Carson Discusses Mogamulizumab as Potential Treatment for CTCL
Kenneth R. Carson, MD, assistant professor, Division of Oncology, Washington University, discusses mogamulizumab as a potential treatment for patients with relapsed or refractory cutaneous T cell lymphoma (CTCL).
Kent W. Mouw, MD, PhD
Latest:
Dr. Mouw on the Role of Radiation Therapy in Prostate Cancer
Kent W. Mouw, MD, PhD, co-director, Bladder Cancer Center, assistant professor, Radiation Oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of radiation therapy in prostate cancer.
Kerin Adelson, MD,
Latest:
Dr. Adelson on Bortezomib plus Fulvestrant for HR+ Breast Cancer
Kerin Adelson, MD, Assistant Professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai, explains the results of a phase II clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.
Kerrie L. Girard, RN, BSN
Latest:
Screening and Management: Distress and the Nurse Navigator, Part II
Cancer and its treatment creates or aggravates psychosocial distress, while unresolved physical and practical problems can also add to the distress of patients attempting to complete their treatment and recovery.
Kerry Rogers, MD
Latest:
Taking Trial Data to the Clinic in MPN and CLL From ASH 2023: Drs Rogers, Brown, and Shammo
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASH Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.